Table III.
Summary of studies with vincristine sub-analysis and/or control group in survivors of childhood cancer exposed to vincristine-containing regimens and the outcome measure of semen analysis.
| Study | Diagnoses | Age at diagnosis (years) | Male survivors (n) | Prepubertal survivors (n) | Chemotherapy treatment | Cranial/infradiaphragmatic irradiation | Control group | Vincristine analysis | Summary finding |
|---|---|---|---|---|---|---|---|---|---|
| Kruseová et al. (2021) a | Various | 0.1–19.1 | 143 | 66 | Various | Yes (n = 34) | Yes | Yesc | 65% of the total survivors had abnormal semen quality. No significant risk illustrated with the administration of topoisomerase and mitotic inhibitors.d |
| Beaud et al. (2019) a | Various | 7.4–11 | 13 | 6 | Vinca alkaloids; alkylating agents; anthracyclines | No | Yesb | Yesc | Non-significant correlation for vinca alkaloid cumulative doses when concerned with DFI and sperm count, illustrating no vinca alkaloid effect.d |
| Müller et al. (1996) | Hodgkin’s disease | 3–17 | 33 | 13 | Various | Yes | Yesb | No | Therapy with alkylating agents and/or gonadal radiation were risk factors for development of azoospermia. |
DFI, DNA fragmentation index.
a
Semen analysis based on World Health Organization laboratory guidelines, for processing and examination of human semen.
b
Healthy age and sex-matched controls.
c
Sub-group analysis for vincristine/vinca alkaloid/topoisomerase inhibitors in childhood survivors.
d
Summary findings relate to chemotherapy treatment received by prepubertal patients (≤12 years of age).